Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 8 Issue 10

Efficacy of GLP-1 Formula on Body Weight in Overweight and Obese Adults

Yung-Hsiang Lin1, Chen-Chen Fu1, Ning-Yuan Wang2, Yi-An Chen2, Ching-Fang Chang3, Shu-Ting Chan4 and Chi-Fu Chiang4*

1Institute of Medical Genetics, TCI GENE INC, Taipei, Taiwan
2Product Marketing Team, TCI GENE INC, Taipei, Taiwan
3Cell Validation Laboratory, TCI GENE INC, Taipei, Taiwan
4Research and Design Center, TCI CO., Ltd., Taipei, Taiwan

*Corresponding Author: Chi-Fu Chiang, Research and Design Center, TCI CO., Ltd., Taipei, Taiwan.

Received: July 11, 2024; Published: September 13, 2024

Abstract

Obesity is a chronic metabolic disease characterized by the excessive accumulation of body fat, affecting the health of millions worldwide. This study aimed to analyze the effectiveness of the GLP-1 Formula (product name: Slim8D No.2) in reducing body weight and exploring its potential as a treatment for obesity. The product's design and main mechanism of action are to enhance the secretion of GLP-1 by colonic L cells. The increase in GLP-1 in the body naturally suppresses appetite, thereby achieving weight loss. In this study, we demonstrated that the GLP-1 Formula product significantly enhanced GLP-1 secretion in NCI-H716 cells. The weight loss trial was conducted from October 25, 2023, to December 31, 2023. Participants took one sachet daily with water before lunch, with each pack containing 7 tablets. The results showed that among the 560 participants, the average weight loss was 4.9 kg by the endpoint. Notably, these 560 participants collectively lost a total of 2,732 kg by the end of the trial. GLP-1 Formula demonstrated promise in reducing body weight and may serve as an effective alternative therapy for treating obesity.

 Keywords: GLP-1 Formula; GLP-1 Secretion; Obesity; Weight loss

References

  1. Lin X and H Li. “Obesity: Epidemiology, Pathophysiology, and Therapeutics”. Frontiers in Endocrinology (Lausanne) 12 (2021): 706978.
  2. Loos RJF and GSH Yeo. “The genetics of obesity: from discovery to biology”. Nature Reviews Genetics 2 (2022): 120-133.
  3. Fruh SM. “Obesity: Risk factors, complications, and strategies for sustainable long-term weight management”. Journal of the American Association of Nurse Practitioners S1 (2017): S3-S14.
  4. Lartey S., et al. “Impact of overweight and obesity on life expectancy, quality-adjusted life years and lifetime costs in the adult population of Ghana”. BMJ Global Health9 (2020).
  5. Muller TD., et al. “Glucagon-like peptide 1 (GLP-1)”. Molecular Metabolism 30 (2019): 72-130.
  6. Wang JY., et al. “GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach”. Frontiers in Endocrinology (Lausanne) 14 (2021): 1085799.
  7. Smits MM and JJ Holst. “Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?” Diabetes/Metabolism Research and Reviews 8 (2023): e3699.
  8. Filippatos TD., et al. “Adverse Effects of GLP-1 Receptor Agonists”. The Review of Diabetic Studies 3-4 (2014): 202-230.
  9. Niyigaba T., et al. “The Extraction, Functionalities and Applications of Plant Polysaccharides in Fermented Foods: A Review”. Foods12 (2021).
  10. Kim KS and HJ Jang. “Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors”. Evidence-Based Complementary and Alternative Medicine (2015): 171742.
  11. Unuofin JO and SL Lebelo. “Antioxidant Effects and Mechanisms of Medicinal Plants and Their Bioactive Compounds for the Prevention and Treatment of Type 2 Diabetes: An Updated Review”. Oxidative Medicine and Cellular Longevity (2020): 1356893.
  12. Wang X., et al. “Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity”. Molecules19 (2021).
  13. Noor J., et al. “Exploring the Impact of the Gut Microbiome on Obesity and Weight Loss: A Review Article”. Cureus 6 (2023): e40948.
  14. Sanders ME., et al. “Safety assessment of probiotics for human use”. Gut Microbes 3 (2010): 164-185.
  15. Rehman SU., et al. “Research progress in the role and mechanism of Leucine in regulating animal growth and development”. Frontiers in Physiology 14 (2023): 1252089.
  16. Gasmi A., et al. “Neurotransmitters Regulation and Food Intake: The Role of Dietary Sources in Neurotransmission”. Molecules1 (2022).
  17. Shan Z., et al. “Theaflavin Chemistry and Its Health Benefits”. Oxidative Medicine and Cellular Longevity (2021): 6256618.
  18. Pan H., et al. “Mechanisms of Body Weight Reduction by Black Tea Polyphenols”. Molecules 12 (2016).
  19. Yang Y., et al. “Effects of soy protein isolate hydrolysates on cholecystokinin released by rat intestinal mucosal cells and food intake in rats”. Journal of Food Science and Technology 12 (2020): 4459-4468.
  20. Velasquez MT and SJ Bhathena. “Role of dietary soy protein in obesity”. International Journal of Medical Sciences 2 (2017): 72-82.
  21. Bozzi Cionci N., et al. “Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases”. Nutrients11 (2018).
  22. Fusco W., et al. “Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota”. Nutrients 9 (2023).
  23. Tolhurst G., et al. “Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2”. Diabetes2 (2012): 364-371.
  24. Pizarroso NA., et al. “A Review on the Role of Food-Derived Bioactive Molecules and the Microbiota-Gut-Brain Axis in Satiety Regulation”. Nutrients2 (2021).
  25. Duan Y., et al. “The role of leucine and its metabolites in protein and energy metabolism”. Amino Acids (2015): 48.
  26. Zeng Y., et al. “Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases”. mBio1 (2024): e0203223.
  27. Shah M and A Vella. “Effects of GLP-1 on appetite and weight”. Reviews in Endocrine and Metabolic Disorders 3 (2014): 181-187.

Citation

Citation: Chi-Fu Chiang., et al. “Efficacy of GLP-1 Formula on Body Weight in Overweight and Obese Adults”.Acta Scientific Medical Sciences 8.10 (2024): 62-67.

Copyright

Copyright: © 2024 Chi-Fu Chiang., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US